Work

Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults

Year: 2024

Type: article

Study design: Observational Study

Abstract: Our global survey reveals no cases of insertional mutagenesis following CAR T-cells in pediatric patients challenging concerns of secondary malignancy risk in this population.This underscores the safety of CAR T-cell therapy in this population, but ongoing surveillance required.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2024013243

Authors: Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M. Hsieh, Kevin McNerney, Rayne H. Rouce, Rebecca A. Gardner, Sara Ghorashian, Nirali N. Shah, Shannon L. Maude

Institutions: Seattle Children's Hospital, Stanford Medicine, Stanford University, Children's Hospital Los Angeles, Lurie Children's Hospital, Texas Children's Hospital, St. Jude Children's Research Hospital, Great Ormond Street Hospital, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Children's Hospital of Philadelphia

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,000

Funders: National Institutes of Health, National Cancer Institute

Award: Development of Novel Approaches to Optimize CAR T-cell Therapies for B-cell Malignancies

OpenAlex ID: W4396604298

FWCI: 4.994

Cites: 18

Cited by: 33

Related to: 10